ISSN: 1859 - 2872
Review of tumor markers for hepatocellular carcinoma
Main Article Content
Keywords
Hepatocellular carcinoma, tumour markers
Abstract
Screening and early detection of hepatocellular carcinoma (HCC) play an important role in management of this disease, affecting the treatment results and patient's survival. Diagnosis of HCC bases on imaging techniques, laboratory tests and cytology and/or pathology that is considered as gold standard. However, it is not every hospital in Vietnam can apply all these diagnostic methods. Today, along with the development of molecular biology, there are many tumor markers detected, supporting for diagnosis and follow-up after treatment. Here we review the role of tumour markers in diagnosis of hepatocellular carcinoma.
Article Details
References
1. Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67: 358-380.
2. Chiang CJ, Yang YW, You SL et al (2013) Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA 310: 974-976.
3. Zheng Z, Liang W, Milgrom DP et al (2014) Liver transplantation versus liver resection in the treatment of hepatocellular carcinoma: A metaanalysis of observational studies. Transplantation 97: 227-234.
4. Altekruse SF, McGlynn KA and Reichman ME (2019) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27: 1485-1491.
5. Tatarinov IS (1964) Detection of embryo-specific Alpha-globulin in the blood serum of a patient with primary liver cancer. Vopr Med Khim 10: 90-91.
6. Taketa K (1990) Alpha-fetoprotein: Reevaluation in Hepatology. Hepatology 12(6): 1420-1432.
7. Vũ Văn Khiên (2000) Giá trị của Alpha-Fetoprotein (AFP) và AFP ái lực với lectin trong chẩn đoán, theo dõi và tiên lượng ung thư biểu mô tế bào gan. Luận án Tiến sỹ Y học, Học viện Quân y.
8. Trevisani F, DIntino PE, Morselli-Labate AM et al (2001) Serum a-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: Influence of HBsAg and anti-HCV status. J. Hepatol 34(4): 570-575.
9 Bruix J, Sherman M (2011) American association for the study of liver diseases. Management of hepatocellular carcinoma: An update. Hepatology 53: 1020-1022.
10. Shiraki K, Taketa K, Tameda Y et al (1995) A clinical study of lectin reactive alpha- fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology 22: 802-807.
11. Aoyagi Y (1952) Carbohydrate based measurement on Alpha-fetoprotein: In the early diagnosis of hepatocellular carcinoma. Glycoconjugate Journal 12: 194-199.
12. Naraki T, Kohno N, Saito H et al (2002) Gamma-carboxyglutamic acid content of hepatocellu-lar carcinoma-associated des-gamma-carboxy prothrombin. Biochim Biophys Acta 1586: 287-298.
13. Liebman HA, Furie BC, Tong M et al (1984) Des- gamma-carboxy (abnormal) prothrombin as a serum marker of hepatocellular carcinoma. N. Engl. J. Med 310: 1427-1431.
2. Chiang CJ, Yang YW, You SL et al (2013) Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA 310: 974-976.
3. Zheng Z, Liang W, Milgrom DP et al (2014) Liver transplantation versus liver resection in the treatment of hepatocellular carcinoma: A metaanalysis of observational studies. Transplantation 97: 227-234.
4. Altekruse SF, McGlynn KA and Reichman ME (2019) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27: 1485-1491.
5. Tatarinov IS (1964) Detection of embryo-specific Alpha-globulin in the blood serum of a patient with primary liver cancer. Vopr Med Khim 10: 90-91.
6. Taketa K (1990) Alpha-fetoprotein: Reevaluation in Hepatology. Hepatology 12(6): 1420-1432.
7. Vũ Văn Khiên (2000) Giá trị của Alpha-Fetoprotein (AFP) và AFP ái lực với lectin trong chẩn đoán, theo dõi và tiên lượng ung thư biểu mô tế bào gan. Luận án Tiến sỹ Y học, Học viện Quân y.
8. Trevisani F, DIntino PE, Morselli-Labate AM et al (2001) Serum a-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: Influence of HBsAg and anti-HCV status. J. Hepatol 34(4): 570-575.
9 Bruix J, Sherman M (2011) American association for the study of liver diseases. Management of hepatocellular carcinoma: An update. Hepatology 53: 1020-1022.
10. Shiraki K, Taketa K, Tameda Y et al (1995) A clinical study of lectin reactive alpha- fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology 22: 802-807.
11. Aoyagi Y (1952) Carbohydrate based measurement on Alpha-fetoprotein: In the early diagnosis of hepatocellular carcinoma. Glycoconjugate Journal 12: 194-199.
12. Naraki T, Kohno N, Saito H et al (2002) Gamma-carboxyglutamic acid content of hepatocellu-lar carcinoma-associated des-gamma-carboxy prothrombin. Biochim Biophys Acta 1586: 287-298.
13. Liebman HA, Furie BC, Tong M et al (1984) Des- gamma-carboxy (abnormal) prothrombin as a serum marker of hepatocellular carcinoma. N. Engl. J. Med 310: 1427-1431.
Article Sidebar
Published
May 10, 2022
Section
Articles
How to Cite
BangM. H., ThịnhN. T., & Khiên V. V. (2022). Review of tumor markers for hepatocellular carcinoma. Tạp Chí Y Dược lâm sàng 108, 17(DB). https://doi.org/10.52389/ydls.v17iDB.1256